Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Dec;20(10):539-546.
doi: 10.1016/j.reumae.2024.11.008.

TNFα-inhibitors cycling with golimumab as second drug in inflammatory arthritis patients: Data from the multicenter GO-REAL registry

Carolina Ayelen Isnardi  1 , Emma Estela Civit De Garignani  2 , Agustín García Ciccarelli  2 , Jimena Sanchez Alcover  2 , Ingrid Strusberg  3 , Marcos Baravalle  3 , Sol Castaños  3 , Liliana Morales  3 , Matias Palombo  3 , Eduardo Albiero  4 , Carla Gobbi  4 , Rodrigo Garcia Salinas  5 , Sebastian Magri  5 , Edson Velozo  6 , Enrique R Soriano  7 , Alfredo Vargas Caselles  7 , Luis Carlos Palomino Romero  7 , Sergio Paira  8 , Romina Calvo  8 , Alberto Ortiz  8 , María Julieta Gamba  9 , Rodolfo Perez Alamino  10 , Hernan Maldonado Ficco  11 , Gustavo Citera  12
Affiliations
Free article
Observational Study

TNFα-inhibitors cycling with golimumab as second drug in inflammatory arthritis patients: Data from the multicenter GO-REAL registry

Carolina Ayelen Isnardi et al. Reumatol Clin (Engl Ed). 2024 Dec.
Free article

Abstract

Introduction/objectives: There are still controversies about the efficacy of cycling to a second tumor necrosis factor inhibitor (TNFi) in patients with inflammatory arthritis. The aim of this study was to evaluate survival, persistence and effectiveness of golimumab (GLM) in patients with rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) with previous experience with other TNFi and to compare these results with TNFi naive patients.

Methods: Observational cohort of consecutive patients with RA, PsA and axSpA who had started treatment with GLM according to medical indication. bDMARD naive and TNFi experienced patients were selected.

Results: A total of 147 (62.3%) bDMARD naive and 45 (19.1%) TNFi experienced patients were included. Patients were followed up for a total of 441.5 patients/year, 55 (28.6%) discontinued GLM, 42 (28.6%) and 13 (28.9%) in each group, respectively (p=0.967). The majority (63.6%) suspended due to inefficacy, followed by lack of access (23.6%) and adverse events (9.1%). Median GLM survival was 74.0 months (95% CI 57.0, 91.0) and 71.0 months (95% CI 37.0, 105.0), in the bDMARD naive and TNFi experienced patients, respectively (p=0.695). Drug persistence at 6, 12, 24 and 36 months was 92.8%, 88.1%, 76.1%, 65.4% and 93.1%, 77.4%, 74.2%, 68.5%, respectively. In the multivariable analysis, having public health insurance was associated with higher risk of drug discontinuation (HR 2.56, 95% CI 1.28-5.00, p=0.008). TNFi experienced patients did not show significantly higher risk of GLM suspension (HR 1.35, 95% CI 0.70-2.57, p=0.370).

Conclusion: In this cohort, TNFi experienced patients had comparable survival and persistence of treatment with GLM. Having public health insurance was associated with lower drug retention rates.

Keywords: Artritis psoriasis; Artritis reumatoidea; Axial spondyloarthritis; Espondiloartritis axial; Golimumab; Inhibidores de factor de necrosis tumoral; Psoriatic arthritis; Rheumatoid arthritis; TNF inhibitors.

PubMed Disclaimer

Publication types